EMED Expands VersaRate^® IP Portfolio, The Global Standard in Infusion Flow Rate Control for Mechanical Pumps

EMED Technologies, a global leader in drug delivery and infusion therapy innovation, today announced the issuance of U.S. Patent No. 12,403,243 that significantly broadens the intellectual property protection for VersaRate^®, the company's flagship variable flow rate controller.

The latest patent further strengthens EMED's comprehensive infusion therapy patent portfolio and underscores the company's commitment to advancing patient safety, clinical excellence, and innovation.

"VersaRate^® represents a transformative platform that redefines infusion therapy by empowering patients and clinicians with safe, adaptable, and intuitive control when using mechanical pumps. With VersaRate^®, we have defined a new standard for flexibility and ease of use in infusion management, enhancing patient care and clinical outcomes."

Paul LambertCEO, EMED Technologies

"This newly granted patent further strengthens EMED's ability to protect its pioneering innovations, establishing a comprehensive legal foundation to deter and address any attempts to unlawfully exploit or replicate EMED's proprietary technology. By fortifying our intellectual property portfolio, we are not only preserving the results of our team's dedication and creativity but also ensuring that EMED remains at the forefront of delivering advanced solutions to our customers with confidence and integrity."

Carl KukkonenLead IP Counsel for EMED Technologies, Partner at Jones Day

The newly issued patent significantly broadens the protection of VersaRate^®'s core design and functionality, with claims that comprehensively cover a wider spectrum of configurations and applications for flow rate controllers. This expanded protection was developed to protect against imitation designs to further strengthen EMED's global leadership in flow control technologies across subcutaneous and intravenous infusion therapies.

VersaRate^® provides a practical solution for adjusting infusion rates when more advanced pumps may not be available. Its straightforward design, proven reliability, and adaptability have made it a preferred choice in both clinical and home settings, particularly for patients with Primary Immunodeficiency (PIDD, CIDP) and other conditions requiring regular infusions.

EMED remains committed to investing in next-generation platforms that prioritize patient comfort, clinician usability, and cost-effectiveness. VersaRate^® remains a cornerstone of EMED's broader strategy to deliver patient-centric solutions that meet the diverse needs of global healthcare systems.

This announcement follows a series of strategic IP developments and underscores EMED's ongoing collaboration with key partners to accelerate access to leading infusion technologies.

For more information about VersaRate^®, VersaRate Plus^®, and EMED's full portfolio of infusion solutions and patents, visit emedtc.com and emedtc.com/patents.